The Market research study titled Gastrointestinal Drugs Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Drug Class, Route of Administration, Application, and Distribution Channel,” the market is expected to reach US$ 71,300.28 million in 2027 from US$ 49,043.38 million in 2019. The market is estimated to grow at a CAGR of 4.9% from 2020 to 2027.
Biologics are beneficial for patients with gastrointestinal disorders who are not responding to conventional treatment. For instance, infliximab, which is derived from monoclonal antibodies to tumor necrosis factor is another modifier of the immune system's actions. Infliximab is given as a series of infusions by vein. This drug can be given to treat moderate to severe Crohn’s disease that has not responded to other drugs, to treat people with fistulas, and to maintain response when the disease is difficult to control. Vedolizumab and natalizumab are drugs for people who have moderate to severe Crohn’s disease that have not responded to TNF inhibitors or other immunomodulating drugs. With the increasing number of biologics in pipeline, the segment is expected to grow at a rapid pace during the forecast period. For instance, Takeda Pharmaceutical Company Limited has five candidates in different phases for various GI indications.
The following manufacturers are covered: Sanofi, GlaxoSmithKline plc, Johnson and Johnson Services, Inc., Bausch Health, AstraZeneca, Takeda Pharmaceutical Company Limited, AbbVie Inc., Bayer AG, Celltrion Healthcare Co.,Ltd, LEXICON PHARMACEUTICALS, INC
Request a sample copy of this report @ https://www.theinsightpartners.com/sample/TIPRE00014758/
Geographically, the Gastrointestinal Drugs market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of MEA), and South and Central America (Brazil, Argentina, and the Rest of SCAM).
The report segments global gastrointestinal drugs market as follows:
By Drug Class
- Acid Neutralizers
- Antidiarrheal and Laxatives
- Anti-Inflammatory Drugs
- Antiemetic and Antinauseants
By Route of Administration
- Inflammatory Ulcerative Colitis
- Crohn's Disease
- Irritable Bowel Syndrome
- Celiac Disease
About The Insight Partners:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defence, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: [email protected]
Gastrointestinal Drugs, Gastrointestinal Drugs Market, Gastrointestinal Drugs Market Analysis